

Research Article

Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion

Małgorzata Trocha,¹ Małgorzata Krzystek-Korpacka ,² Anna Merwid-Ląd,¹ Beata Nowak,¹ Małgorzata Pieśniewska,¹ Piotr Dziegiel,^{3,4} Agnieszka Gomułkiewicz,³ Przemysław Kowalski,⁵ Dorota Diakowska ,⁶ Adam Szelağ,¹ and Tomasz Sozański ¹

¹Department of Pharmacology, Wrocław Medical University, Jana Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland

²Department of Medical Biochemistry, Wrocław Medical University, Chałubińskiego 10, 50-368 Wrocław, Poland

³Department of Human Morphology and Embryology, Division of Histology and Embryology, Wrocław Medical University, Chałubińskiego 6a, 50-368 Wrocław, Poland

⁴Department of Physiotherapy, University School of Physical Education, I.J. Paderewskiego 35, 51-612 Wrocław, Poland

⁵Department of Pathomorphology and Oncological Cytology, Wrocław Medical University, Borowska 213, 50-556 Wrocław, Poland

⁶Division of Nervous System Diseases, Department of Clinical Nursing, Faculty of Health Sciences of Wrocław Medical University, K. Bartla 5, 51-618 Wrocław, Poland

Correspondence should be addressed to Tomasz Sozański; tsoz@wp.pl

Received 30 March 2019; Revised 22 July 2019; Accepted 21 September 2019; Published 31 October 2019

Guest Editor: Aneta Radziwon-Balicka

Copyright © 2019 Małgorzata Trocha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Ischemia/reperfusion (IR) is the main cause of liver damage after transplantation. We evaluated the effect of sitagliptin (STG) on oxidative stress parameters in the rat liver under IR. **Methods.** Rats were treated with STG (5 mg/kg) (S and SIR) or saline solution (C and CIR). Livers from CIR and SIR were subjected to ischemia (60 min) and reperfusion (24 h). During reperfusion, aminotransferases (ALT and AST) were determined in blood samples. Thiobarbituric acid reactive substances (TBARS), superoxide dismutase (SOD), catalase (CAT), paraoxonase-1 (PON1), glutathione peroxidase (GPx), and the mRNA expression of SOD1 were determined in liver homogenates after reperfusion. Different regions of livers were also histologically evaluated. **Results.** The PON1 activity was higher, and the TBARS level was lower in SIR than in CIR. There was an inverse relationship between TBARS and PON1 levels in the whole cohort. The GPx activity was lower in ischemic than in nonischemic groups regardless of the STG treatment. In SIR, the SOD1 activity was higher compared to that in CIR. In S, the expression of SOD1 mRNA was the highest of all examined groups and positively correlated with the SOD1 activity in the whole animal cohort. During IR aminotransferases, the activity in the drug-treated group was lower in all examined points of time. In drug-treated groups, the percentage of steatosis was higher than that in nontreated groups regardless of IR. **Conclusions.** The protective effect of STG on the rat liver, especially its antioxidant properties, was revealed under IR conditions.

1. Introduction

Ischemia/reperfusion (IR) is the main cause of liver injury that occurs during such procedure as transplantation or hepatectomy [1]. Initially, this damage is caused by ischemia, but further, it is aggravated by reperfusion. Among the many phenomena occurring in the IR, there is an excessive production of free radicals and the development

of oxidative stress [2, 3]. Lipid peroxidation is one of the manifestations of oxidative imbalance accompanying rapid tissue reoxygenation and responsible for detrimental effects of IR. The process is initiated by the attack of reactive oxygen species (ROS) on double bonds of membrane phospholipids, glycolipids, and cholesterol. Malondialdehyde among others, are end products of lipid peroxidation. Lipid peroxidation, if not counteracted by antioxidants,

leads to the deterioration of cellular membranes, loss of cell integrity, and cell death [4].

Superoxide dismutases (SODs) are antioxidant enzymes that convert superoxide radicals to oxygen and hydrogen peroxide [2]. There are three isoforms of SOD in mammals: SOD1, SOD2, and SOD3. SOD1, the major cytoplasmic isoenzyme which activity depends on the presence of the Cu and Zn, is expressed highly in selected tissues, mainly in the liver [5]. Hydrogen peroxide is reduced by selenium-containing enzyme—glutathione peroxidase (GPx) to water. Additionally, it is converted to water and molecular oxygen by catalase (CAT)—antioxidant enzyme located mainly in peroxisomes [6]. GPx is the most tightly associated with lipid peroxidation. In addition to preventing hydroxyl radical from forming, GPx is also responsible for two-electron reduction of hydroperoxides, primary products of lipid peroxidation, averting their one-electron reduction that facilitates propagation phase of the process [4]. Paraoxonase-1 (PON1) is a liver-synthesized esterase and lactonase characterized by broad substrate specificity. Best known is the enzyme form residing on HDL and involved in the protection of lipoproteins against lipid peroxidation. Apart from circulation, PON1 is present mainly in the liver where it participates in the inactivation of oxidative by-products, generated during biotransformation of xenobiotics in the microsomes [7]. Intracellular form of PON1 was also shown to involve in the stabilization of lipid membranes and the enhancement of their integrity under oxidative stress conditions [8]. Thiobarbituric acid reactive substances (TBARS) are the final lipid peroxidation product. The accumulation of malondialdehyde (MDA) occurs already in the ischemic phase and ROS-generating reperfusion exacerbating lipid peroxidation [9]. Due to inhibition of oxidative phosphorylation [10], ischemia accelerates processes, such as glycolysis and ketogenesis, which yield methylglyoxal as a by-product. Methylglyoxal is a glycoside factor initiating lipid peroxidation, leading to the formation of MDA [11]. Moreover, MDA can be synthesized enzymatically from thromboxane A₂ [4], the synthesis of which is upregulated during ischemia [12].

Because extensive damage of the liver subjected to IR depends, among others, on the intensity of oxidative stress, the search for such substances that would enhance the antioxidant defense is justified. Sitagliptin (STG) belongs to a group of oral hypoglycemic drugs that, through inhibition of the dipeptidyl peptidase-4 (DPP-4) activity, prolong the half-life and thus action of incretins—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [13, 14]. STG is approved in more than 130 countries worldwide in monotherapy or in combination with other hypoglycemic drugs for the treatment of patients with type 2 diabetes. STG is generally well tolerated, with gently or moderately intensified adverse events [15]. The choice of STG could be based on the additional properties of this drug, such as antioxidative action, that have been reported in some works [16, 17].

The aim of this work was to evaluate the potential antioxidative and hepatoprotective properties of STG administered chronically to rats prior to liver IR procedure.

2. Materials and Methods

2.1. Animals. The study was carried out on Wistar male rats at the age of 2–3 months. Animals were housed in individual chambers in standard conditions (a 12:12 h light-dark cycle, humidity 45–60%, continuous ventilation, and the temperature maintained at 21–23°C).

2.1.1. Ethical Approval and Informed Consent. All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. The experiment protocol was approved by the 1st Local Ethics Committee on the Animal Research of the Institute of Immunology and Experimental Therapy Polish Academy of Sciences in Wrocław (# 80/2012 of December 5, 2012).

2.2. Chemicals. Sitagliptin (Januvia, tabl. 100 mg; MSD, Poland), heparin (Heparinum WZF, amp. 25000 U/5 ml; Polfa Warszawa, Poland), ketamine hydrochloride (Bioketan, Vetoquinol Biowet, Poland), medetomidine hydrochloride (Domitor, amp. 1 mg/ml, Orion Pharma, Finland), butorphanol tartrate (Morphasol, amp. 4 mg/ml, aniMedica GmbH, Germany), 0.9% sodium chloride solution (Polpharma S.A., Poland), and Ringer's solution (Polfa Lublin S.A., Poland) were used in the study.

2.3. Experimental Design. Following adaptation period, rats were divided randomly into 4 groups. In group C ($n = 9$) and CIR ($n = 9$), animals were not treated with STG. In group S ($n = 8$) and SIR ($n = 10$), animals received STG (5 mg/kg p.o.) once a day for 2 weeks prior to the surgical procedure. Livers from groups SIR and CIR were subjected to the IR procedure. To determine the initial activity of ALT and AST, blood samples were obtained from the tail vein after the STG treatment.

2.4. IR Procedure. After intramuscular injection of medetomidine hydrochloride (0.1 mg/kg), ketamine hydrochloride (7 mg/kg), and butorphanol tartrate (2 mg/kg), animals were subjected to midline laparotomy. In groups CIR and SIR, branches of the hepatic artery and portal vein were occluded with a microvascular clip, which caused 70% of the liver (median and left lateral lobes) to be ischemic. Rats were given heparin (200 U/kg) to prevent blood coagulation. The clip was removed after 60 min of ischemia to allow reperfusion for 24 h. At 2, 6, and 24 h of reperfusion, samples of blood were collected to determine the activity of aminotransferases. Once the experiment was terminated, livers were weighted and ischemic lobes were isolated. A part of the liver lobes was placed in the RNAlater RNA Stabilization Reagent (Qiagen, Germany) and used for real-time PCR. Remaining ischemic liver tissue was homogenized, and supernatant was collected.

In S and C groups, rats underwent the same anesthesia and surgical procedure as in the ischemic groups (CIR and SIR), but after midline laparotomy, the branches of the portal vein and hepatic artery were not occluded. Blood samples

were obtained at the same time points as in the case of ischemic groups. After 24 hours of reperfusion, the same lobes of livers were isolated as in ischemic groups. All surgical procedures with or without I/R were blindly performed by the same experienced team of researchers.

2.5. The Homogenization of Isolated Fragments of the Liver. Liver tissue fragments (400-500 mg) were homogenized 1:2 (*w/v*) in Tris-EDTA buffer pH 7.2 (10 mM Tris, 1 mM EDTA, 1 mM MgCl₂, and 150 mM KCl) with 1% deoxycholate, 1 mM PMSF, and 1% Triton X-100, using ceramic lysing matrix beads and the FastPrep-24™ homogenizer (MP Biomedicals, LCC, CA, USA). Homogenates were centrifuged (14,000 × g, 10 min, 4°C), and supernatants were collected, aliquoted, and stored at -80°C. Prior to analyses, homogenate samples were diluted with Tris-EDTA buffer or respective assay buffers with optimal dilution factors established for each assay by serial dilutions.

2.6. Oxidative Stress Parameters and Biochemical Analyses. The concentrations of thiobarbituric acid reactive substances (TBARS) were determined with the thiobarbituric acid spectrophotometric assay [18] with the addition of butylated hydroxytoluene (Fluka, Switzerland). The activities of copper-zinc superoxide dismutase (SOD1) and GPx were measured using Superoxide Dismutase Assay Kits and Glutathione Peroxidase Assay Kits (Cayman Chemical, MI, USA), according to the manufacturer's instructions and expressed as units (U/g for SOD) or kilounits (kU/g for GPx) per gram of liver tissue. The CAT activity was measured according to the procedure described by Bartosz [19], in which the decrease in absorbance at 240 nm, caused by decomposition of hydrogen peroxide (H₂O₂), was assessed for one minute. One unit of an enzyme activity is defined as one millimole of degraded H₂O₂ per minute. The enzyme activity was expressed as kilounits per gram (kU/g) of liver tissue.

The PON1 activity was determined spectrophotometrically by measuring the rates of phenyl acetate (Sigma-Aldrich, St. Louis, MO) hydrolysis, according to the Arylesterase/Paraoxonase Assay Kit protocol (ZeptoMetrix Co., Buffalo, NY). The enzyme activity was expressed in kilounits per gram (kU/g) of liver tissue. One unit (U) of the enzyme activity was defined as one mmol of released phenol per 1 liter per minute in 25°C. The enzyme activity towards phenyl acetate (PON1 arylesterase activity) is considered as a surrogate for the enzyme concentration [20]. All measurements were conducted at least in duplicates, and technical replicates were averaged.

Serum activities of aminotransferases (ALT and AST) and protein concentration in homogenates were assayed using a commercial enzymatic method in a certified laboratory.

2.7. RNA Isolation and Reverse Transcription. Total RNA was isolated from the studied tissue samples with RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. To eliminate genomic DNA contamination, on-column DNase digestion was performed using RNase-

Free DNase Set (Qiagen, Hilden, Germany). Quantity and purity of RNA samples were assessed by measuring the absorbance at 260 and 280 nm with NanoDrop1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). First-strand cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA).

2.8. Real-Time PCR. The mRNA expression of SOD1 was determined by real-time PCR with 7900HT Fast Real-Time PCR System and TaqMan Gene Expression Master Mix (Applied Biosystems, Carlsbad, CA, USA). Beta-2 microglobulin (B2M) was used as reference gene. For the reactions, the following sets of primers and TaqMan probes were used: Rn00566938_m1 for SOD1 and Rn00560865_m1 for B2M (Applied Biosystems, Carlsbad, CA, USA). All reactions were performed in triplicates in standardized thermal cycling conditions, including polymerase activation at 50°C for 2 min, denaturation at 94°C for 10 min, and 40 cycles of denaturation at 94°C for 15 s followed by annealing and synthesis at 60°C for 1 min. The relative amount of SOD1 at the mRNA level (RQ) was calculated by the 2^{-ΔΔCt} method.

2.9. Histological Examination. Different regions of the isolated lobes of livers from ischemic and nonischemic groups were fixed in 10% formalin and embedded in paraffin. Sections of 4.5 μm were made and stained with hematoxylin-eosin. Then, they were histologically evaluated under a light microscope for the severity of ischemic necrosis, degree of steatosis as percentage of the microscopic field (small cytoplasmic vacuoles containing lipids or single fat droplets displacing the nuclei of hepatocytes), neutrophil infiltration, and destruction of hepatic architecture.

3. Statistical Analysis

Data distribution and homogeneity of variances were tested using Kolmogorov-Smirnov and Levene tests, respectively. Normally distributed data (SOD1 activity and expression, CAT, and aminotransferases) were expressed as means ± SD and analyzed using one-way ANOVA with Bonferroni correction for multiple testing, followed by post hoc test. Nonnormally distributed data (TBARS, PON1, and GPx) were expressed as medians with interquartile range and analyzed using Kruskal-Wallis *H* test with the Conover post hoc analysis. Statistical analysis of the effect of the drug and time of reperfusion on the aminotransferase activity was performed using repeated measures ANOVA. Correlation analysis was conducted using Spearman (ρ) or Pearson (r) correlation tests, depending on the data distribution. All tests were two-tailed, and hypotheses were considered positively verified if $p < 0.05$. The analyses were performed using MedCalc Statistical Software version 17.4.4 (MedCalc Software bvba, Ostend, Belgium; <https://www.medcalc.org>; 2017) and Statistica (13.1).

4. Results

4.1. Aminotransferases. After 2 weeks of the STG administration, before surgical procedure, the activity of ALT in rats

from treated groups (S+SIR) was significantly lower compared to nontreated groups (C+CIR) ($p < 0.05$). At 2 h of reperfusion, the significant increase in the ALT activity was noticed regardless of STG administration (CIR vs. C, $p < 0.01$ and SIR vs. S, $p < 0.05$). Values of ALT in the STG-treated ischemic group were insignificantly lower than in the nontreated group. Differences between AST activities were also significant between nonischemic and ischemic nontreated groups (CIR vs. C, $p < 0.01$). After 6 h of reperfusion, the activity of ALT was statistically higher in the nontreated ischemic group compared to the nonischemic group (CIR vs. C, $p < 0.01$). In STG-treated groups, this difference was close to the significance threshold (SIR vs. S, $p = 0.06$). After 24 h of reperfusion, the activity of aminotransferases was the highest in the ischemic nontreated group (CIR vs. C, $p < 0.01$ for AST and $p < 0.05$ for ALT). The increase in the aminotransferase activity in STG-treated groups was not significant. Hence, therein, in the case of ALT, that difference was close to the significance threshold (SIR vs. CIR, $p = 0.05$), and in the case of AST, that difference was significant (SIR vs. CIR, $p < 0.01$) (Figures 1(a) and 1(b)).

4.2. Parameters of Oxidative Stress. The differences in TBARS were noticed in nontreated groups. The concentration of TBARS was significantly greater in IR-exposed livers compared to nonischemic group (CIR vs. C, $p < 0.05$). In drug-treated groups, the concentration of TBARS was lower in the ischemic group compared to S (SIR vs. S, $p < 0.05$). Hence, in the STG-treated ischemic group, the level of this parameter was significantly lower compared to the nontreated ischemic group (SIR vs. CIR, $p < 0.01$) (Figure 2(a)).

The activity of PON1 was significantly lower in the nontreated ischemic group than in the nonischemic group (CIR vs. C, $p < 0.05$). Significant difference was also noticed between nontreated and drug-treated nonischemic groups (C vs. S, $p < 0.05$). In IR-exposed groups, the activity of PON1 was statistically higher in STG-treated groups compared to nontreated one (CIR vs. SIR, $p < 0.05$) (Figure 2(b)). There was an inverse relationship between TBARS accumulation and PON1 activity in whole cohort ($\rho = -0.42$, $p = 0.011$). The association was stronger in IR animals (CIR and SIR) ($\rho = -0.64$, $p = 0.003$).

In IR-exposed groups, the activity of GPx was significantly lower than in nonischemic groups regardless of STG treatment (CIR vs. C, $p < 0.05$; SIR vs. S, $p < 0.01$) (Figure 2(c)). No significant differences in the activity of CAT between experimental groups were noticed. Ischemic-dependent statistically insignificant decrease in the activity of CAT was visible only in nontreated groups (Figure 2(d)).

Ischemic-dependent decrease in the activity of SOD1 in groups nontreated with STG was close to the significance threshold (CIR vs. C, $p = 0.07$). In drug-treated groups, the SOD1 activity was similar regardless of IR. Hence, in the IR conditions in the drug-treated group, the SOD1 activity was significantly higher compared to that in the nontreated group (SIR vs. CIR, $p < 0.05$) (Figure 2(e)).

4.3. SOD1 mRNA Expression. In the nonischemic group treated with STG, the expression of SOD1 mRNA significantly increased and was the highest of all examined groups (S vs. C and SIR, $p < 0.05$, and S vs. CIR, $p < 0.01$) (Figure 2(f)).

SOD1 expression positively but moderately correlated with the SOD1 activity in the whole animal cohort ($r = 0.41$, $p = 0.015$). However, this association resulted from a tight relationship between parameters in nontreated animals and was nonexistent in STG-treated ones (Figure 3). Comparison of correlation coefficients between C and CIR groups showed them to be similarly high ($r = 0.72$, $p = 0.027$ and $r = 0.73$, $p = 0.025$, respectively).

4.4. Histological Findings. No significant differences in the hepatic structure were seen in both ischemic and nonischemic groups of rats. Livers from those groups featured normal architecture, and only slight degree of necrosis and neutrophil infiltration was seen in ischemic groups regardless of the STG treatment. In drug-treated groups, the percentage of steatosis was statistically higher than that in nontreated groups. Described differences were visible in both ischemic and nonischemic groups (CIR vs. SIR, $p < 0.05$, and C vs. S, $p < 0.01$) (Figure 4).

5. Discussion

A body of evidence has gathered concerning protective effect of new drugs on hepatic cells during IR, providing rationale for new therapeutic strategies. Among others, glucose-lowering activity of incretins, and hence indirectly of STG, translates into reduced oxidative stress, condition fueled by hyperglycemia [21]. Moreover, STG has been found to be an efficient scavenger of reactive oxygen species (ROS), directly reducing superoxide generation in various organs [22], but the STG effect on oxidative balance in the liver remains unknown. Our work was carried out to understand the effect of STG on the oxidative stress parameters in the liver under IR conditions.

IR resulted in decreased activities of all enzymes examined in our work, but the difference was significant solely in the case of GPx. There is still no consensus regarding IR effect on the SOD1 activity. While some of the authors have shown it to be decreased [23–25], others have found it to be elevated [26] or, as in the case of IR in mice's kidneys, showed the response to be depended on sex [27]. Therefore, to verify SOD1 status, we examined also SOD1 gene expression. Corroborating its reduced activity, relative SOD1 expression was insignificantly decreased by ca 10% upon IR conditions. Interestingly, SOD1 and GPx activities were affected by IR to the same extent (ca 18%), which corresponds well with 20% drop in glutathione level, an electron donor in the reactions catalyzed by GPx, reported recently by Weng et al. [23].

STG has been shown to increase the SOD, CAT, and GPx activities in kidneys [16], organs with the highest DPP-4 activity [21]. However, this effect was observed only in rats with diabetes. In the kidneys of healthy animals, the SOD activity decreased slightly, the CAT activity increased slightly, and the GPx activity remained unchanged [28].




FIGURE 1: Influence of IR and STG treatment on activity of ALT (a) and AST (b). Values are presented as the mean + SD. Group C, nontreated and nonsubjected to IR; group CIR, nontreated and subjected to IR; group S, STG-treated and nonsubjected to IR; group SIR, STG-treated and subjected to IR. Specific comparisons: * $p < 0.05$ and ** $p < 0.01$ (compared to C), # $p < 0.05$ (compared to S), and $\Delta\Delta p < 0.01$ (compared to CIR).

These observations may imply that beneficial effects of drug are displayed solely in the presence of an additional factor increasing the oxidative stress. IR is another condition, in which STG treatment has been associated with improved antioxidant status both at systemic level [29] and locally in myocardium [24], kidney [28], and hippocampus [30]. In our work, carried out on rat livers, the protective effect of STG was visible only under IR conditions. In the ischemic liver, the CAT and SOD1 activities decreased insignificantly in untreated groups but remained unchanged in the STG group. Therefore, in the case of SOD1, significant differences were observed between treated and untreated groups.

Interestingly, SOD1 expression in our STG-treated nonischemic livers was significantly upregulated, which, however, did not translate into increased enzyme activity. The discrepancy between drug effect on enzyme gene expression and activity could also be found in the case of GPx in kidneys: its mRNA expression decreased [31] but enzymatic activity increased [16]. One must keep in mind that many factors may affect translation and thus up- or downregulate expression on protein level as compared to mRNA copy numbers or, in the case of the enzymes, also modulate their activity. Indeed, antioxidant enzymes are sensitive to oxidative damage themselves. Moderate oxidative imbalance stimulates expression of antioxidant enzymes through activation of *Nrf2*, but it may also diminish their activity by causing oxidative modifications, e.g., oxidation of cysteine thiols. However, the correlation analysis of SOD1 expression and activity showed them to be tightly and positively correlated with nontreated animals, but it was completely abolished in STG-treated animals. Taken together, results showed that STG differently affected SOD1 at transcriptional and enzyme

activity levels and was responsible for the disruption of the association between both parameters.

Nrf2 is a key transcription factor responsible for induction of antioxidant enzymes synthesis. It was recently demonstrated that STG downregulated the expression of *Nrf2* in rat kidneys, with concomitant upregulation of its inhibitor—Keep1. These findings imply that, at least in kidneys, antioxidant action of STG is associated rather with direct reduction of intracellular ROS or with increased stability of GLP-1. Since we observed upregulation of SOD1 expression in the liver, it would be of interest to investigate the drug effect on hepatic *Nrf2* [31].

A reduction of hepatic PON1 activity during lipid peroxidation and liver damage was an early occurring phenomenon, what was shown in animal models [32]. Accordingly, a drop in the PON1 activity has accompanied also hepatic IR injury [33, 34]. Corroborating these observations, we found PON1 to be significantly decreased in the ischemic nontreated group. In line with the beneficial effect on the oxidative balance attributed to STG during IR [25, 28, 30], the enzyme activity in the ischemic drug-treated group was restored and significant differences were observed between treated and untreated groups. However, the PON1 activity was diminished in drug-treated animals not subjected to IR. These results seem to imply that STG *per se* might have a negative impact on the enzyme. A positive correlation between the PON1 activity and insulin resistance was shown [35, 36]. The high glucose concentration was shown to induce activation of specific protein (SP)-1 [37, 38], a transcription factor activating the PON1 promoter in cultured hepatocytes [37]. STG increasing the sensitivity of tissues to insulin may negatively affect the




FIGURE 2: Influence of IR and STG treatment on TBARS (a), PON-1 (b), GPx (c), CAT (d), SOD1 (e), and mRNA for SOD1 (f) levels. Values are presented as the mean + SD. Group C, nontreated and nonsubjected to IR; group CIR, nontreated and subjected to IR; group S, STG-treated and nonsubjected to IR; group SIR, STG-treated and subjected to IR. Specific comparisons: * $p < 0.05$ (compared to C), # $p < 0.05$ and ## $p < 0.01$ (compared to S), Δ $p < 0.05$ and ΔΔ $p < 0.01$ (compared to CIR), and † $p < 0.05$ (compared to SIR).

expression of PON1 in the liver. However, functional studies are needed to determine the exact effect of STG on the enzyme.

Simultaneously with the decreased activity of PON1 in untreated ischemic livers, a significant increase in TBARS concentration was observed. Our findings corroborate earlier reports on increased accumulation of lipid peroxidation products in response to IR injury in the liver [9, 26, 39–42]. STG has been reported to possess antioxidant properties manifested, among others, by its capability to limit lipid peroxidation [22]. Under IR conditions, the effect of STG lowering MDA accumulation has previously been observed in the brain [30], kidney [28], and heart [25]. We showed that MDA formation was reduced after STG treatment also in livers subjected to IR. However, without pathology such as IR or diabetes, STG seems to have an opposite effect and increase the accumulation of TBARS, what was also noticed by other authors [29, 43].

While unexpected, this finding is consistent with the diminishing effect of the drug on PON1 and a close negative correlation between liver PON1 activity and accumulation of TBARS observed in our study as well. Therefore, considering the role of PON1 in protection against lipid peroxidation [7, 8], enhanced lipid peroxidation in STG-treated animals might directly result from drug-induced inhibition of PON1. Surprisingly, in studies evaluating beneficial effects of various drugs on IR injury, a control drug-treated group has frequently been missing, also in the case of STG [25, 30].

The histological evaluation of liver specimens showed no significant differences in IR-dependent liver structure. Only slight degree of necrosis and neutrophil infiltration was observed in ischemic groups. To monitor the liver dysfunction, which intensifies with the duration of IR, we determine the activity of aminotransferases—enzymes released from damaged hepatocytes [44, 45]. As in our previous works [46–48], we have also demonstrated in this work that the




FIGURE 3: Comparison of correlation between SOD1 expression and activity in control (nontreated) (a) and STG-treated (b) animals. Data presented as regression line with 95% confidence interval (dashed lines).




FIGURE 4: Histopathological examination of liver tissue. Histological examination (stained with hematoxylin-eosin, magnification $\times 400$, bar $50 \mu\text{m}$) from group C, rats nontreated and nonsubjected to IR (a); group CIR, rats nontreated and subjected to IR (b); group S, rats treated with STG and not subjected to IR (c); and from group SIR, rats treated with STG and subjected to IR (d). No significant differences in the hepatic structure were seen in both ischemic and nonischemic groups of rats. In drug-treated groups, the percentage of steatosis was statistically higher than that in nontreated groups (CIR vs. SIR, $p < 0.05$, and C vs. S, $p < 0.01$).

aminotransferase activity was significantly increased, most pronounced in the nontreated ischemic group. Therefore, despite a minimal histological abnormality, we may suspect a low-degree liver injury evoked by IR.

The STG is minimally metabolized in the liver, and over 80% is excreted with the urine in unaltered form [49]. Therefore, this medicine has a safe and beneficial

pharmacokinetics even in patients with liver damage. The STG safety profile assessed in many studies is rather good, and the risk of liver damage does not increase. In clinical trials, the use of STG alone or in combination with other oral antidiabetic agents did not cause alterations in AST or ALT [50, 51]. There are only a few cases of serious liver damage after STG treatment [52, 53]. In our work, the

effect of STG therapy on liver damage probably depends on the initial conditions. The higher steatosis rates observed in STG-treated groups suggested detrimental effects of the drug itself during chronic treatment. On the other hand, the aminotransferase activity before and during IR in the drug-treated group was lower at all time points, and in the 24-hour reperfusion, the difference was significant. Such results, however, indicate a protective effect of STG, which is more visible in harmful conditions, such as IR in our case.

6. Conclusions

Summing up, the action of STG strongly depends on additional factors increasing the oxidative stress, such as IR. In the nonischemic group, the effect of STG on oxidative parameters was invisible or even negative. However, under IR, the action of this drug is beneficial. Also, despite the small degree of steatosis, the aminotransferase activity analysis does not suggest any hepatotoxic action of STG. Contrarily, even a slight protective effect of this drug was seen, especially in IR conditions.

Although significant results have been obtained in this work, the limitations of this study should be considered. In our work, we observed the effect of STG only on the parameters of oxidative stress in the rat liver subjected to IR. It will be important in further studies to also examine other markers of liver injury during IR, especially the ones associated with inflammation and apoptosis. To better explain the STG's mechanism of protective action, we also plan to explore a grip point of this drug. Furthermore, we are now aware, that by extending the duration of administration and using higher STG doses, a more pronounced effect of this drug may be achieved. And finally, the limitations of a partial liver ischemia model used in this work need to be considered. During the induced ischemia of the middle and left lateral lobe, there is an increased blood flow in the rest of the liver, which can affect liver function and regeneration. Exchange of oxygen from perfused to ischemic part of the liver may affect the values of oxidative stress parameters obtained in this experiment.

Abbreviations

ALT:	Aminotransferase alanine
AST:	Aminotransferase aspartate
CAT:	Catalase
DPP-4:	Dipeptidyl peptidase-4
GIP:	Glucose-dependent insulinotropic polypeptide
GLP-1:	Glucagon-like peptide-1
GPx:	Glutathione peroxidase
H ₂ O ₂ :	Hydrogen peroxide
IR:	Ischemia/reperfusion
MDA:	Malondialdehyde
PON1:	Paraoxonase-1
ROS:	Reactive oxygen species
SOD:	Superoxide dismutase
STG:	Sitagliptin
TBARS:	Thiobarbituric acid reactive substances.

Data Availability

The laboratory data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest.

Authors' Contributions

Małgorzata Trocha conceived and designed the study, conducted the experiment, participated in the acquisition of laboratory data, analyzed and interpreted the data, drafted the article, and finally approved and guaranteed the manuscript. Małgorzata Krzystek-Korpacka assayed the redox parameters and PON1 in liver homogenates and drafted the manuscript part of the Materials and Methods section concerning determination of redox parameters and PON1. Anna Merwid-Ląd conducted the experiment and revised the manuscript to be submitted. Beata Nowak analyzed and interpreted the data and revised the manuscript to be submitted. Małgorzata Pieśniewska conducted the experiment on animals. Piotr Dzięgiel assayed the SOD1 mRNA expressions, contributed to the writing of the manuscript, and revised the manuscript to be submitted. Agnieszka Gomułkiewicz assayed the SOD1 mRNA expressions, drafted the manuscript part of the Materials and Methods section concerning SOD1 mRNA expressions, and revised the manuscript to be submitted. Przemysław Kowalski carried out the histopathological evaluations. Dorota Diakowska collected the laboratory data and revised the manuscript to be submitted. Adam Szeląg analyzed and interpreted the data, contributed to the writing of the manuscript, and revised the manuscript to be submitted. Tomasz Sozański conceived and designed the study, analyzed and interpreted the data, contributed to the writing of the manuscript, and revised the manuscript to be submitted. All authors read and approved the manuscript.

Acknowledgments

The study was financially supported by the statutory means of Wrocław Medical University (ST-555).

References

- [1] A. Cobreros, L. Sainz, B. Lasheras, and E. Cenarruzabeitia, "Hepatotoxicity of ethanol: protective effect of calcium channel blockers in isolated hepatocytes," *Liver*, vol. 17, no. 2, pp. 76–82, 1997.
- [2] C. Fan, R. M. Zwacka, and J. F. Engelhardt, "Therapeutic approaches for ischemia/reperfusion injury in the liver," *Journal of Molecular Medicine*, vol. 77, no. 8, pp. 577–592, 1999.
- [3] A. Stanek, A. Gadowska-Cicha, K. Gawron et al., "Role of nitric oxide in physiology and pathology of the gastrointestinal tract," *Mini Reviews in Medicinal Chemistry*, vol. 8, no. 14, pp. 1549–1560, 2008.
- [4] A. Ayala, M. F. Muñoz, and S. Argüelles, "Lipid peroxidation: production, metabolism, and signaling mechanisms of

- malondialdehyde and 4-hydroxy-2-nonenal,” *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 360438, 31 pages, 2014.
- [5] Y. Fukai and M. Ushio-Fukai, “Superoxide dismutases: role in redox signaling, vascular function, and diseases,” *Antioxidants & Redox Signaling*, vol. 15, no. 6, pp. 1583–1606, 2011.
- [6] S. Wassmann, K. Wassmann, and G. Nickenig, “Modulation of oxidant and antioxidant enzyme expression and function in vascular cells,” *Hypertension*, vol. 44, no. 4, pp. 381–386, 2004.
- [7] J. Camps, J. Marsillach, and J. Joven, “Measurement of serum paraoxonase-1 activity in the evaluation of liver function,” *World Journal of Gastroenterology*, vol. 15, no. 16, pp. 1929–1933, 2009.
- [8] D. A. Chistiakov, A. A. Melnichenko, A. N. Orekhov, and Y. V. Bobryshev, “Paraoxonase and atherosclerosis-related cardiovascular diseases,” *Biochimie*, vol. 132, pp. 19–27, 2017.
- [9] S. M. Lee, M. J. Park, T. S. Cho, and M. G. Clemens, “Hepatic injury and lipid peroxidation during ischemia and reperfusion,” *Shock*, vol. 13, no. 4, pp. 279–284, 2000.
- [10] F. Z. Meerson, V. E. Kagan, Y. P. Kozlov, L. M. Belkina, and Y. V. Arkhipenko, “The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart,” *Basic Research in Cardiology*, vol. 77, no. 5, pp. 465–485, 1982.
- [11] N. Murata-Kamiya and H. Kamiya, “Methylglyoxal, an endogenous aldehyde, crosslinks DNA polymerase and the substrate DNA,” *Nucleic Acids Research*, vol. 29, no. 16, pp. 3433–3438, 2001.
- [12] A. Yan, T. Zhang, X. Yang et al., “Thromboxane A2 receptor antagonist SQ29548 reduces ischemic stroke-induced microglia/macrophages activation and enrichment and ameliorates brain injury,” *Scientific Reports*, vol. 6, article 35885, 2016.
- [13] J. E. Campbell and D. J. Drucker, “Pharmacology, physiology, and mechanisms of incretin hormone action,” *Cell Metabolism*, vol. 17, no. 6, pp. 819–837, 2013.
- [14] C. F. Deacon, “Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes,” *Expert Opinion on Investigational Drugs*, vol. 16, no. 4, pp. 533–545, 2007.
- [15] L. J. Scott, “Sitagliptin: a review in type 2 diabetes,” *Drugs*, vol. 77, no. 2, pp. 209–224, 2017.
- [16] J. Vaghasiya, N. Sheth, Y. Bhalodia, and R. Manek, “Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes,” *Regulatory Peptides*, vol. 166, no. 1-3, pp. 48–54, 2011.
- [17] Y. T. Chen, T. H. Tsai, C. C. Yang et al., “Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction,” *Journal of Translational Medicine*, vol. 11, no. 1, pp. 1–19, 2013.
- [18] C. A. Rice-Evans, A. T. Diplock, and M. C. R. Symons, *Techniques in free radical research*, Elsevier Science Publishers BV, Amsterdam, 1991.
- [19] G. Bartosz, *Druga twarz tlenu. Wolne rodniki w przyrodzie. (The other face of oxygen. Free radicals in the environment)*, Wydawnictwo Naukowe PWN, Warszawa, 2nd edition, 2004.
- [20] L. G. Costa, A. Vitalone, T. B. Cole, and C. E. Furlong, “Modulation of paraoxonase (PON1) activity,” *Biochemical Pharmacology*, vol. 69, no. 4, pp. 541–550, 2005.
- [21] C. Mega, E. Teixeira-de-Lemos, R. Fernandes, and F. Reis, “Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes,” *Journal Diabetes Research*, vol. 2017, article 5164292, 14 pages, 2017.
- [22] L. Liu, J. Liu, X. Y. Tian et al., “Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress,” *Antioxidants & Redox Signaling*, vol. 21, no. 11, pp. 1571–1581, 2014.
- [23] J. Weng, W. Li, X. Jia, and W. An, “Alleviation of ischemia-reperfusion injury in liver steatosis by augmenting of liver regeneration is attributed to antioxidation and preservation of mitochondria,” *Transplantation*, vol. 101, no. 10, pp. 2340–2348, 2017.
- [24] Z. Chen, T. Ding, and C.-G. Ma, “Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice,” *Biochemical and Biophysical Research Communications*, vol. 493, no. 2, pp. 1143–1150, 2017.
- [25] G. Chang, P. Zhang, L. Ye et al., “Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model,” *European Journal of Pharmacology*, vol. 718, no. 1-3, pp. 105–113, 2013.
- [26] M. Arslan, F. Metin Çomu, A. Küçük, L. Oztürk, and F. Yaylak, “Dexmedetomidine protects against lipid peroxidation and erythrocyte deformability alterations in experimental hepatic ischemia reperfusion injury,” *Libyan Journal of Medicine*, vol. 7, no. 1, article 18185, 2012.
- [27] M. P. Schneider, J. C. Sullivan, P. F. Wach et al., “Protective role of extracellular superoxide dismutase in renal ischemia/reperfusion injury,” *Kidney International*, vol. 78, no. 4, pp. 374–381, 2010.
- [28] A. Nuransoy, A. Beytur, A. Polat, E. Samdanci, M. Sagir, and H. Parlakpinar, “Protective effect of sitagliptin against renal ischemia reperfusion injury in rats,” *Renal Failure*, vol. 37, no. 4, pp. 687–693, 2015.
- [29] S. Karabulut, Z. M. Coskun, and S. Bolkent, “Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats,” *Pharmacological Reports*, vol. 67, no. 5, pp. 846–853, 2015.
- [30] A. E. El-Sahar, M. M. Safar, H. F. Zaki, A. S. Attia, and A. A. Ain-Shoka, “Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic pathway,” *Life Sciences*, vol. 126, pp. 81–86, 2015.
- [31] E. Civantos, E. Bosch, E. Ramirez et al., “Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 10, pp. 207–222, 2017.
- [32] N. Ferre, J. Camps, M. Cabre, A. Paul, and J. Joven, “Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis,” *Metabolism*, vol. 50, no. 9, pp. 997–1000, 2001.
- [33] H. Kandis, S. Karapolat, U. Yildirim, A. Saritas, S. Gezer, and R. Memisogullari, “Effects of *Urtica dioica* on hepatic ischemia-reperfusion injury in rats,” *Clinics*, vol. 65, no. 12, pp. 1357–1361, 2010.
- [34] A. Tüfek, O. Tokgöz, I. Aliosmanoglu et al., “The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats,” *International Journal of Surgery*, vol. 11, no. 1, pp. 96–100, 2013.

- [35] M. Bednarska-Makaruk, A. Graban, W. Lipczyńska-Łojkowska et al., "Positive correlation of paraoxonase 1 (PON1) activity with serum insulin level and HOMA-IR in dementia. A possible advantageous role of PON1 in dementia development," *Journal of the Neurological Sciences*, vol. 324, pp. 172–175, 2013.
- [36] A. Yamada, T. Shoji, H. Tahara, M. Emolo, and Y. Nishizawa, "Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population," *Metabolism Clinical and Experimental*, vol. 50, no. 7, pp. 805–811, 2001.
- [37] Y. Ikeda, T. Suehiro, K. Ariei, Y. Kumon, and K. Hashimoto, "High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes," *Metabolism*, vol. 57, no. 12, pp. 1725–1732, 2008.
- [38] K. Beishline and J. Azizkhan-Clifford, "Sp1 and the 'hallmarks of cancer'," *The FEBS Journal*, vol. 282, no. 2, pp. 224–258, 2015.
- [39] D. Giakoustidis, N. Kontos, S. Iliadis et al., "Severe total hepatic ischemia and reperfusion: relationship between very high alpha-tocopherol uptake and lipid peroxidation," *Free Radical Research*, vol. 35, no. 2, pp. 103–109, 2001.
- [40] N. Yun, J. W. Kang, and S. M. Lee, "Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: molecular evidence of its antioxidant and anti-inflammatory properties," *The Journal of Nutritional Biochemistry*, vol. 23, no. 10, pp. 1249–1255, 2012.
- [41] J. Kim, H. Y. Kim, and S. M. Lee, "Protective effects of geniposide and genipin against hepatic ischemia/reperfusion injury in mice," *Biomolecules & Therapeutics*, vol. 21, no. 2, pp. 132–137, 2013.
- [42] E. Tak, G. C. Park, S. H. Kim et al., "Epigallocatechin-3-gallate protects against hepatic ischaemia-reperfusion injury by reducing oxidative stress and apoptotic cell death," *The Journal of International Medical Research*, vol. 44, no. 6, pp. 1248–1262, 2016.
- [43] Z. M. Coskun, M. Koyuturk, S. Karabulut, and S. Bolkent, "CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin," *Pharmacological Reports*, vol. 69, no. 4, pp. 822–829, 2017.
- [44] E. E. Montalvo-Javé, M. A. García-Puig, T. Escalante-Tattersfield, J. Peña-Sánchez, H. Vázquez-Meza, and J. A. Ortega-Salgado, "Biochemical analysis and lipid peroxidation in liver ischemic preconditioning," *Cirugía y Cirujanos*, vol. 79, no. 2, pp. 132–140, 2011.
- [45] C. Wu, P. Wang, J. Rao et al., "Triptolide alleviates hepatic ischemia/reperfusion injury by attenuating oxidative stress and inhibiting NF- κ B activity in mice," *The Journal of Surgical Research*, vol. 166, no. 2, pp. e205–e213, 2011.
- [46] M. Trocha, A. Merwid-Łąd, E. Chlebda, M. Pieśniewska, T. Sozański, and A. Szeląg, "Effect of simvastatin treatment on rat livers subjected to ischemia/reperfusion," *Pharmacological Reports*, vol. 62, no. 4, pp. 757–762, 2010.
- [47] M. Trocha, A. Merwid-Łąd, E. Chlebda et al., "Influence of ezetimibe on selected parameters of oxidative stress in rat liver subjected to ischemia/reperfusion," *Archives of Medical Science*, vol. 10, no. 4, pp. 817–824, 2014.
- [48] M. Trocha, A. Merwid-Łąd, M. Pieśniewska et al., "Age-related differences in function and structure of rat livers subjected to ischemia/reperfusion," *Archives of Medical Science*, vol. 14, no. 2, pp. 388–395, 2018.
- [49] D. J. Drucker and M. A. Nauck, "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes," *The Lancet*, vol. 368, no. 9548, pp. 1696–1705, 2006.
- [50] I. Raz, M. Hanefel, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus," *Diabetologia*, vol. 49, no. 11, pp. 2564–2571, 2006.
- [51] M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial," *Diabetes, Obesity and Metabolism*, vol. 9, no. 2, pp. 194–205, 2007.
- [52] M. Toyoda-Akui, H. Yokomori, F. Kaneko et al., "A case of drug-induced hepatic injury associated with sitagliptin," *Internal Medicine*, vol. 50, no. 9, pp. 1015–1020, 2011.
- [53] B. N. Gross, L. B. Cross, J. Foard, and Y. Wood, "Elevated hepatic enzymes potentially associated with sitagliptin," *The Annals of Pharmacotherapy*, vol. 44, no. 2, pp. 394–395, 2010.